Management: Surgery, Adjuvant Decisions, Molecular Profiling, and Rare Tumors

Surgery as the mainstay, risk categories and adjuvant radiation/chemotherapy guidance, POLE/MMR/TP53 molecular testing to guide therapy, frontline chemo + immunotherapy updates, second-line strategies, and an overview of uterine sarcomas and carcinosarcoma approaches.